Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF Mutant Metastatic Colorectal Cancer Patients

Rona Yaeger\textsuperscript{1}, Andrea Cercek\textsuperscript{1}, Eileen M. O’Reilly\textsuperscript{1}, Diane L. Reidy\textsuperscript{1}, Nancy Kemeny\textsuperscript{1}, Tamar Wolinsky\textsuperscript{1}, Marinela Capanu\textsuperscript{2}, Marc J. Gollub\textsuperscript{3}, Neal Rosen\textsuperscript{1,4}, Michael F. Berger\textsuperscript{5}, Mario E. Lacouture\textsuperscript{1}, Efsevia Vakiani\textsuperscript{5}, Leonard Saltz\textsuperscript{1}

From the Departments of \textsuperscript{1}Medicine, \textsuperscript{2}Epidemiology-Biostatistics, \textsuperscript{3}Radiology, the \textsuperscript{4}Program in Molecular Pharmacology and Chemistry, and \textsuperscript{5}Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065

Running title: RAF plus EGFR inhibition for BRAF mutant mCRC

Keywords: BRAF; RAF inhibitor; colorectal cancer

Supported by Genentech, a research award from the Society of Memorial Sloan-Kettering Cancer Center (R.Y.), and a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (R.Y.).

Address correspondence to: Rona Yaeger, MD, Memorial Sloan Kettering Cancer Center, 300 E 66\textsuperscript{th} Street, 10\textsuperscript{th} Floor, New York, NY 10065. Tel 646-888-4179

Disclosures: Consulting – Genentech/Roche (MEL, LS); Consulting – Amgen (RY, MEL); Research funding – Genentech/Roche (RY, EMO); Research funding – Amgen (NK)

Trial registration ID: NCT01791309
STATEMENT OF TRANSLATIONAL RELEVANCE

New therapies are needed for BRAF mutant mCRC, an aggressive subset of colorectal cancer with decreased responsiveness to standard therapies. In this pilot trial, we find that the combination of panitumumab and vemurafenib is well-tolerated and has biologic activity in the majority of patients with BRAF mutant mCRC.
ABSTRACT

Purpose: BRAF mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of epidermal growth factor receptor (EGFR) signaling occurs in colorectal tumor cells treated with RAF inhibitors and that the addition of an EGFR inhibitor enhances antitumor activity. These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy for treating BRAF V600E mCRC.

Experimental Design: We undertook a pilot trial to assess the response rate and safety of the BRAF inhibitor vemurafenib combined with anti-EGFR antibody panitumumab in patients with BRAF mutant mCRC. Patients received standard approved doses of panitumumab and vemurafenib.

Results: Fifteen patients were treated. Performance status was ECOG 0 in four patients (27%) and ECOG 1 in 11 patients (73%). All patients had progressed through at least one standard treatment regimen, and eight (53%) had received previous fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy. Treatment was well tolerated, with less cutaneous toxicity than would be expected with either agent, and no cases of keratoacanthomas/squamous cell carcinomas. Tumor regressions were seen in 10 of 12 evaluable patients with partial responses in two patients (100% and 64% regression lasting 40 and 24 weeks, respectively), and stable disease lasting over six months in two patients.

Conclusion: Combined RAF and EGFR inhibition is well tolerated, with less cutaneous toxicity than would be expected with either agent, and results in modest clinical activity in this highly aggressive and chemo-resistant subset of CRC.
INTRODUCTION

*BRAF* mutation occurs in up to 10% of metastatic colorectal cancer (mCRC) and is associated with a worse prognosis(1, 2). Patients with metastatic *BRAF*-mutated CRC are less responsive to current chemotherapy(2-4) and do not benefit from anti-epidermal growth factor receptor (EGFR) antibodies in the chemotherapy-refractory setting(5-7). *BRAF* mutant mCRC has a predilection for spread to the peritoneum and less frequently presents with metastases limited to the liver(8, 9). New systemic therapies are particularly needed for this group.

*BRAF* encodes a protein directly downstream from RAS in the canonical mitogen-activated protein kinase (MAPK) cascade. In its active GTP-bound form, RAS activates RAF by recruiting RAF and simulating RAF dimerization(10, 11). *BRAF* mutations in CRC occur most commonly at the V600 hotspot and lead to constitutive activation of V600E BRAF, which signals as a monomer(12).

Selective inhibitors of RAF, such as vemurafenib and dabrafenib, have recently been developed and have entered the clinic. In wild-type cells, where RAF signals as a dimer, these inhibitors bind to one protomer in the RAF dimer, but trans-activate the other protomer and thus paradoxically activate ERK signaling(12). This is responsible for much of the toxicity of these drugs and can lead to induction of keratoacanthomas and, rarely, accelerate the growth of tumors with mutant *RAS* when these drugs are inadvertently administered to patients with such tumors(13, 14). In contrast, binding of the drug to BRAF V600E monomers inhibits their activity. Since these drugs inhibit ERK signaling only in tumors with *BRAF* mutations, and not in normal cells, they have a broad therapeutic index.
In *BRAF* mutant tumors, adaptive resistance to RAF inhibitors is due to feedback reactivation of RAS. RAF inhibitors block extracellular-regulated kinase (ERK) signaling, releasing upstream receptors from ERK-dependent negative feedback, leading to increased ligand-dependent signaling through upstream receptors, RAS activation, and the generation of RAF inhibitor-resistant RAF dimers(15). This is associated with a rebound in ERK signaling after initial potent inhibition in tumor cells exposed to RAF inhibitors. This rebound is modest in *BRAF* mutant melanomas and these tumors can be very sensitive to RAF inhibitors. Vemurafenib causes objective responses in about 50% of patients and improves overall survival compared to standard chemotherapy with dacarbazine(16). In contrast, vemurafenib showed minimal effect against *BRAF* mutant CRC in an extension cohort of the phase I study(17). In CRC cell lines, RAF inhibitors cause transient potent inhibition of the pathway followed by robust pathway reactivation(18). Pharmacodynamic studies in melanoma patients treated with vemurafenib suggest that near complete inhibition of ERK is necessary to effectively inhibit tumor growth(19), so the lack of potent durable inhibition of the pathway likely plays a role in the ineffectiveness of this drug in mCRC. Prahallad *et al* and Corcoran *et al* showed that vemurafenib treatment of *BRAF* V600E colorectal tumors is associated with reactivation of EGFR signaling(18, 20). Inhibition of EGFR enhanced ERK pathway inhibition by vemurafenib and the combination was able to suppress the growth of *BRAF* mutant CRC in *in vitro* and *in vivo* preclinical models.

Based on these data, we undertook a pilot study to evaluate the clinical efficacy and safety of combined EGFR and BRAF inhibition in *BRAF* V600E mutant CRC.

**METHODS**
Study Design

Fifteen patients were enrolled between February 2013 and May 2014. Patients participating in this study were required to have \textit{BRAF} V600E mutated metastatic colorectal adenocarcinoma. Patients had to have progressed through one or more standard chemotherapy regimens, but were permitted to have received any number of prior regimens. Additional eligibility criteria included: age $\geq$ 18 years; Eastern Cooperative Oncology Group performance status of 0-1; measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); adequate hematological, liver, and renal function; and ability to swallow oral medication. Patients were excluded if they received previous anti-EGFR targeting antibodies (cetuximab or panitumumab). The study protocol was approved by the Institutional Review Board/Privacy Board and patients provided their written informed consent prior to study treatment and related procedures.

Tumor Sequencing

\textit{BRAF} V600E mutation was confirmed in all cases using a mass-spectrometry based assay (Sequenom, San Diego, CA) that evaluated for hotspot mutations in the genes \textit{BRAF}, \textit{KRAS}, \textit{NRAS}, \textit{PIK3CA}, \textit{MEK}, \textit{AKT}, \textit{EGFR}, and \textit{ERBB2}, as previously described(21). All slides were reviewed for appropriate tumor content by a pathologist before analysis. Mutations were confirmed either by a separate Sequenom assay or by Sanger sequencing.

DNA from tumors and matched normal tissue from five cases were also analyzed on our custom next-generation sequencing platform, IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). The IMPACT assay is a targeted exome capture assay with ultradeep sequencing coverage (median, 570x) using Illumina HiSeq 2000. Target specific-probes for
hybrid selection were designed as previously described\(22, 23\) to capture all protein-coding exons of 341 oncogenes, tumor suppressor genes, and components of pathways deemed actionable by targeted therapies (for full list see Supplementary Table S1).

**Immunohistochemistry**

Immunohistochemical analysis of hMLH1, hMSH2, hMSH6, or PMS2 expression was used to evaluate tumor mismatch repair (MMR) protein status. Expression of phosphorylated ERK and cyclin D1 were also tested by immunohistochemistry (IHC). Antibodies used were rabbit monoclonal antibodies and were obtained from Cell Signaling (phospho-ERK) or ThermoScientific Lab Vision (cyclin D1). The staining was scored 0-3+ based on the percentage of tumor cells stained.

**Study Treatment and Procedures**

Patients received the FDA-approved starting doses of panitumumab (6mg/kg IV every 14 days) and vemurafenib (960mg orally twice daily). To allow for planned correlative studies, patients started panitumumab on day one of the study and then started vemurafenib on day 8 of the study. Concurrent treatment with panitumumab and vemurafenib continued until objective progression of disease or unacceptable toxicity.

Since panitumumab and vemurafenib had not been previously combined in a clinical trial, this trial included a toxicity hold after enrollment of six patients. If one or fewer dose limiting toxicities (DLTs) were observed in the first six patients then accrual would proceed at the specified dose. However if two or more DLTs occurred then we would reassess trial doses of vemurafenib and panitumumab and would enroll subsequent patients at a reduced dose level. DLTs were defined as grade 4 hematologic toxicities or grade 3 non-hematologic toxicities.
(except for grade 3 rash that responded to maximal supportive treatments and did not require
dose reduction, grade 3 nausea, vomiting, or diarrhea that responded to maximal supportive
treatment(s) within 48 hours, or electrolyte disturbances that responded to correction within 24
hours).

The first 10 patients enrolled in the trial were required to have pre- and post-vemurafenib
biopsies for planned correlative studies. Baseline biopsies were obtained 4-7 days after starting
panitumumab, and on-treatment biopsies were obtained 12-16 days after starting vemurafenib.

Patients were evaluated for response by CT scan every 8 weeks. Responses were determined
using RECIST criteria (version 1.1). Safety was evaluated using the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0, based on
recorded adverse events, physical examinations, and clinical laboratory assessments.

**Statistical Design**

The trial’s primary endpoint was overall response. Secondary endpoints were progression-free
survival (PFS), overall survival (OS), and adverse event profile of this regimen. An additional
secondary objective was to assess the ability of this combination to inhibit ERK signaling in
tumors.

This was a pilot trial with a goal of accrual of 15 patients to check for evidence of activity of this
regimen. Fifteen patients allows estimation of the overall response rate to within ±25%.

Primary statistical analyses were performed on data from the population comprising all patients
who receive any dose of study drug. Any patient who dropped out prior to the 8 week
assessment was deemed a non-responder. The study protocol pre-specified that the results of this trial would be considered encouraging for activity if 2 or more of the 15 patients responded.

RESULTS

Patient Characteristics

Table 1 lists characteristics of the 15 patients enrolled in this pilot trial. Median age on enrollment was 62 years (range 22-83 years). Seven patients (47%) were male. Eleven patients (73%) had a right-sided primary tumor. Eight patients (53%) had stage IV disease at diagnosis. Performance status was ECOG 0 in four patients (27%) and ECOG 1 in 11 patients (73%). All patients had progressed through at least one standard treatment regimen, and eight (53%) had received previous fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy. Eleven patients had MMR IHC, and one patient’s tumor was MMR-deficient.

Tumor mutational profile

Tumor sequencing was performed with a mass-spectrometry assay for hotspot mutations in the $BRAF$, $KRAS$, $NRAS$, $PIK3CA$, $MEK$, $AKT$, $EGFR$, and $ERBB2$ genes. All tumors had a $BRAF$ V600E mutation. One case had a concurrent $PIK3CA$ E545K mutation. No other concurrent mutations in this panel of genes were identified.

Five cases were analyzed by deep sequencing using the IMPACT assay, a custom next generation sequencing assay of all protein-coding exons of 341 oncogenes, tumor suppressor genes, and components of pathways deemed actionable by targeted therapies. The genetic alterations identified are listed in Supplemental Table 2. A mean of 11 somatic mutations (range 6-17) was identified in these tumors. Two cases had alterations in WNT signaling: an $APC$
truncating mutation in one case and a missense mutation in β-catenin in the other. No alterations in WNT pathway genes were detected in the other three cases analyzed. All cases had an alteration in TP53. No other shared alterations were identified in these five samples and no additional alterations in the RAS/RAF pathway were identified.

**Adverse events**

The combination of panitumumab and vemurafenib was well-tolerated overall and no dose limiting toxicities were identified in the first six patients enrolled, allowing patients to continue to enroll at the full doses of panitumumab and vemurafenib. Table 2 lists adverse events attributed to treatment. Acneiform rash and fatigue, primarily grade 1, were the most frequently observed treatment-related adverse events. Four patients experienced grade 3 alkaline phosphatase elevations. One patient experienced grade 4 AST/ALT elevation with treatment that resolved on cessation of vemurafenib, but recurred on re-challenge with the drug. Two patients developed small bowel obstruction requiring surgical bypass while on trial. Both incidents were felt to be unrelated to study medications, and the patients were able to restart therapy after their recovery. One patient had a bowel perforation while on study, which was attributed to progression of disease. Six patients on this trial required dose reductions of vemurafenib (two for arthralgias, one for transaminitis, one for fatigue, one for neutropenia, and one for photosensitivity rash), and one patient required a dose reduction of panitumumab (for acneiform rash).

When compared to patients on single agent vemurafenib and panitumumab, patients in our study developed a lower incidence and severity of acneiform rash (40% grade 1, 13% grade 2), maculopapular rash (13%), palmar-plantar erythrodysesthesia syndrome (7%), papillomas (7%)
and cutaneous squamous cell carcinoma/keratoacanthoma (0%), likely due to opposing effects of vemurafenib (activation) and panitumumab (inhibition) on ERK signaling in epidermal keratinocytes. Figure 1 shows representative photographs of dermatologic adverse events seen with the panitumumab/vemurafenib combination.

**Pharmacodynamic studies**

Nine patients underwent pre-and post-vemurafenib biopsies. Specimens were collected after 4-7 days of panitumumab treatment and after 15-17 days of combination treatment. Expression of phosphorylated ERK and cyclin D1 was assessed in the biopsy specimens by IHC. Representative sections for phospho-ERK (Figure 2A) and cyclin D1 (Figure 2B) are shown for a patient each with partial response, stable disease, and progression in the left, middle, and right panels, respectively. Samples obtained after treatment with panitumumab exhibited substantial expression of phosphorylated ERK and of cyclin D1 in all cases. Tumor levels of phosphorylated ERK and cyclin D1 were markedly reduced after 15 days of the combination regimen in all samples. These findings suggest that, as expected, ERK signaling in BRAF mutant CRC is not effectively inhibited with anti-EGFR antibodies alone and addition of vemurafenib further suppresses ERK signaling. Interestingly, in the patient who did not respond to treatment, cyclin D1 levels were incompletely suppressed with the panitumumab/vemurafenib combination (Figure 2B, rightmost panel).

**Tumor Response**

Treatment response was assessed in 12 patients (Figure 3A). Two additional patients died from disease progression before the first scan and are reported as non-responders. One patient withdrew consent after four weeks of treatment because of persistent abdominal pain despite
treatment. This patient is reported as a non-responder, but had a CT scan of the abdomen and pelvis at time of withdrawal that showed 16% regression.

Two patients (13%) had confirmed partial responses (100% and 64% regression) lasting 40 and 24 weeks, respectively, and two patients had stable disease lasting over six months with tumor regressions of 24% and 18%. Four additional patients demonstrated some degree of tumor shrinkage (range 4% to 20%) which did not meet formal response criteria, including a patient who was removed from the trial after 8 weeks for grade 4 hepatotoxicity attributed to vemurafenib and a patient who withdrew consent after 8 weeks to undergo hepatectomy.

Two patients in this trial had concurrent mutations that activate phosphatidylinositol 3-kinase (PI3K) signaling (supplemental table 2). One patient had a PIK3CA E545K mutation and one patient had a hotspot PTEN R173C mutation. Both patients had stable disease as best response, with tumor regression of 20% and 24% by RECIST, respectively, with the vemurafenib plus panitumumab combination. One patient had a MMR-deficient tumor, and this patient had 18% tumor regression by RECIST on her first assessment scan but had to stop treatment for recurrent, grade 4 AST/ALT elevations with treatment.

Survival

Figure 3B shows time on treatment for patients participating in this study. Median progression-free survival for panitumumab plus vemurafenib was 3.2 months (95% CI: 1.6-5.3 months) (Figure 4A). Median overall survival was 7.6 months (95% CI: 2.1-not reached) (Figure 4B).

DISCUSSION
In this pilot trial, we found that the combination of panitumumab and vemurafenib was well-tolerated and had biologic activity in the majority of patients with \textit{BRAF} mutant mCRC. Twenty percent of patients treated experienced tumor regression lasting greater than 6 months. This trial provides support for the concept that combined selective RAF and EGFR inhibition is a viable strategy with which to treat these tumors. Notably, the response rate seen is similar to the activity of panitumumab alone in \textit{KRAS} wild-type tumors\cite{24}, consistent with the notion that EGFR is the dominant receptor driving ERK signaling in about one fifth of CRCs.

\textit{BRAF} mutation has been validated as a poor prognostic factor associated with shorter survival in clinical series and in clinical trials in mCRC\cite{1, 2, 25}. Based on current clinical trial data, the use of \textit{BRAF} mutation as a predictive marker for response to anti-EGFR antibodies is not straightforward. Patients with \textit{BRAF} mutant mCRC do not benefit from anti-EGFR antibodies in the chemotherapy-refractory setting\cite{5-7}. In the first-line setting, analysis of a series of \textit{BRAF} mutant mCRC patients who received cetuximab together with active chemotherapy, either FOLFOX or FOLFIRI, suggested an improvement in PFS and OS with the addition of cetuximab, but the difference did not reach statistical significance\cite{26}. This observation is also limited by the un-preplanned analysis that combined data from two separate trials and needs to be validated in prospective, randomized trials. In this trial, all patients treated with vemurafenib and panitumumab had progressed through at least one line of standard chemotherapy, so would not be expected to benefit from the panitumumab alone. Panitumumab is given together with vemurafenib here to inhibit the reactivation of EGFR signaling that occurs with RAF inhibition.

Deep sequencing results were available for five cases. Sequencing revealed no other alterations in the RAS/RAF pathway. WNT pathway alterations were detected in only two of these five cases. Data from the Cancer Genome Atlas in colorectal cancer suggest that WNT pathway
alterations may be less common in hypermutated and BRAF mutant colorectal cancer(27) and this has been attributed to tumor development through the serous serrated pathway, rather than the classic adenoma-carcinoma pathway. Interestingly, all five cases had alterations in TP53 suggesting a possible role of p53 inactivation in the progression of BRAF mutant mCRC. Two cases had mutational activation of PI3K signaling, and both experienced minor responses to treatment, suggesting that concurrent PI3K activation does not exclude benefit from combined RAF and EGFR inhibition.

This study included a safety assessment after enrollment of six patients because of concern for overlapping toxicity of these two agents, particularly dermatologic toxicity. Dermatologic adverse events have been reported in 95% and 74% of patients on vemurafenib and panitumumab, respectively(28, 29). Vemurafenib has been associated with a mostly maculopapular rash (64%), palmar-plantar erythrodysesthesia (60%), alopecia (45%), photosensitivity (52%), xerosis (19%), and cutaneous squamous cell carcinomas/keratoacanthomas (cuSCC/KA) (26%/14%). Conversely, through the inhibition of EGFR in skin, panitumumab leads to the development of an acneiform rash (90%), xerosis (10%), and paronychia (27%). The low degree of dermatologic toxicity seen suggests that EGFR antibodies, like MEK inhibitors(30-32), can reduce cutaneous toxicity, particularly cuSCC/KA development, caused by RAF inhibitors and that the driver of RAS activation in the skin is dominantly EGFR.

Clinical trial data suggest skin rash may serve as a surrogate marker of EGFR-targeted therapy efficacy and correlates with objective tumor response and OS with anti-EGFR antibody therapy in mCRC(33-35). However, the reduced skin toxicity with the vemurafenib/panitumumab combination cannot be taken as a surrogate for ineffective EGFR inhibition because of the
opposing effects of these two agents in the skin. Specifically, vemurafenib and panitumumab have additive effects against ERK signaling in the *BRAF* V600E mutated tumors cells, but opposing effects on ERK signaling in wild-type cells. In wild-type cells, such as skin, vemurafenib binds and stabilizes the active dimeric conformation of RAF kinase, resulting in RAF activation and increased downstream ERK signaling(36). This effect opposes ERK inhibition from EGFR blockade in the skin, leading to decreased skin toxicity. In contrast, in the *BRAF* V600E mutated tumor, the addition of vemurafenib to panitumumab enhances ERK inhibition, as evidenced by the marked inhibition of ERK expression in the biopsy specimen collected after 15 days of vemurafenib/panitumumab treatment compared to the baseline biopsy specimen collected after treatment with panitumumab alone. Unlike wild-type RAFs, the V600E mutant BRAF does not require dimerization for its activity and is able to signal as a monomer(12). Vemurafenib binds to the BRAF V600E monomer and inhibits its kinase activity and downstream signaling, enhancing inhibition of ERK signaling from EGFR blockade in the tumor cells.

A notable toxicity seen with the combination was abnormalities of liver function tests, which were seen in a third of patients participating in this trial. Twenty percent of patients had grade 3 alkaline phosphatase elevations, compared to 3% of patients in the BRAF Inhibitor in Melanoma-3 (BRIM-3) study, the vemurafenib registration trial in melanoma patients(16). Two patients experienced grade 4 transaminitis with treatment. Patients with mCRC, who nearly all have liver metastasis, may be at greater risk for hepatic toxicity with vemurafenib. These results suggest that liver laboratory studies need to be carefully followed when combining RAF and EGFR inhibitors in these patients.
Although the results suggest some efficacy from combined RAF and EGFR inhibition, the regressions are smaller in magnitude and shorter in duration that hoped for or suggested by animal models. Recent studies suggest that, in most cases, adaptive and acquired resistance to RAF inhibitors are due to processes that prevent adequate inhibition of ERK signaling by the drug(37). These findings suggest that BRAF V600E is a key driver and that selection of resistance involves changes that prevent its inhibition. Correlative studies in this trial suggest that the combination of vemurafenib and panitumumab markedly inhibits ERK signaling in colorectal tumors, but the degree of inhibition is variable. Pharmacodynamic data from the phase I trial of vemurafenib suggest that substantial ERK inhibition is required for tumor growth inhibition, and even a small residual degree of ERK signaling may be sufficient to maintain tumor growth(19). In this trial, one patient who did not respond to treatment had inhibition of phosphorylated ERK with the panitumumab/vemurafenib combination in his on-treatment biopsy, but incomplete inhibition of cyclin D1. Future, larger studies may clarify if this regimen sufficiently inhibits ERK signaling in $BRAF$ mutant mCRC and if cyclin D1 provides a good pharmacodynamics marker.

The enhanced activity of the combination compared to historical data with vemurafenib alone is consistent with preclinical data and the hypothesis that reactivation of EGFR signaling mediates adaptive resistance to RAF inhibitors in colorectal cancer. Our study is limited by a small sample size and the absence of a vemurafenib only control arm. There are several other studies testing combinations of selective RAF and EGFR inhibitors in this population, and our response rate of 13% is in line with the preliminary reports from these other studies. In VE-BASKET, a basket trial of vemurafenib in nonmelanoma solid tumors harboring $BRAF$ V600 mutations, patients with CRC were treated with vemurafenib plus cetuximab following a 3+3 dose
escalation. Preliminary results from this trial report two partial responders and six patients with stable disease in ten patients treated with this combination(38). The combination of encorafenib, another selective RAF inhibitor, and cetuximab in a phase I study of 18 patients, reported in abstract form thus far, led to partial responses in two patients(39). Early data from a phase I/II study of the combination of dabrafenib and panitumumab indicate that seven of eight evaluable patients achieved stable disease as the best overall response to this treatment(40).

Outcomes from our pilot trial, together with the abstract presentations from these other trials of RAF/EGFR inhibition in \textit{BRAF} mutant mCRC, suggest that this regimen represents a first step towards treating these tumors. However, only a subset of patients respond to this regimen and responses are not durable, all lasting less than one year. Future analysis of progression specimens and further studies of RAF/EGFR combination regimens will clarify the need for profound ERK inhibition and the role of parallel pathways in these tumors to refine our approach to the treatment of \textit{BRAF} mutant mCRC.

\textbf{ACKNOWLEDGMENTS}

We thank Jaclyn M. Verghis and Michael Fox for assistance with data collection.
REFERENCES


38. Tabernero J, Chan E, Baselga J, Blay J, Chau I, Hyman DM, et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or


Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>BRAF Mutant metastatic colorectal cancer patients (n=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Mean 63 years (22-83) Median 62 years</td>
</tr>
<tr>
<td>Gender</td>
<td>Male 47% (n=7) Female 53% (n=8)</td>
</tr>
<tr>
<td>Site of primary tumor*</td>
<td>Right-colon 71% (n=10) Left-colon 29% (n=4)</td>
</tr>
<tr>
<td>Stage at diagnosis</td>
<td>Stage I 7% (n=1) Stage II 7% (n=1) Stage III 33% (n=5) Stage IV 53% (n=8)</td>
</tr>
<tr>
<td>Line of treatment</td>
<td>2(^{nd}) line 53% (n=8) 3(^{rd}) line 57% (n=7)</td>
</tr>
<tr>
<td>ECOG performance status</td>
<td>ECOG 0 27% (n=4) ECOG 1 73% (n=11)</td>
</tr>
</tbody>
</table>

*One patient presented with synchronous adenocarcinoma in the right and left sides of the colon.
Table 2. Adverse events.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rash acneiform</td>
<td>6 (40%)</td>
<td>2 (13%)</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4 (27%)</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Alkaline phosphatase elevation</td>
<td>0</td>
<td>2 (13%)</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>Arthralgias</td>
<td>2 (13%)</td>
<td>2 (13%)</td>
<td>0</td>
</tr>
<tr>
<td>Dry skin/xerosis</td>
<td>4 (27%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AST/ALT elevation</td>
<td>0</td>
<td>0</td>
<td>3 (20%)*</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>2 (13%)</td>
<td>1 (7%)</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>1 (7%)</td>
<td>1 (7%)</td>
<td>0</td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>2 (13%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pruritis</td>
<td>2 (13%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Rash maculopapular</td>
<td>2 (13%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>0</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Keratosis</td>
<td>0</td>
<td>1 (7%)</td>
<td>0</td>
</tr>
<tr>
<td>Palmar-plantar erythrodysesthesia syndrome</td>
<td>0</td>
<td>1 (7%)</td>
<td>0</td>
</tr>
<tr>
<td>Weight loss</td>
<td>0</td>
<td>1 (7%)</td>
<td>0</td>
</tr>
<tr>
<td>Alopecia</td>
<td>1 (7%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1 (7%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>1 (7%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nasal vestibulitis</td>
<td>1 (7%)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Grade 4 AST/ALT elevations were noted twice in the same patient, occurring after initial treatment and on re-challenge with vemurafenib.
LEGENDS

Figure 1 – Representative photographs of dermatologic adverse events showing (A) acneiform rash, (B) dry skin, and (C) cymotrichous.

Figure 2 - Representative sections from IHC analysis of (A) phosphorylated ERK and (B) cyclin D1 expression. Samples collected before vemurafenib treatment, after 1 week of panitumumab therapy, are on the top row, and samples collected after two weeks of combined panitumumab and vemurafenib treatment are on the bottom row.

Figure 3 - (A) Waterfall plot showing best response radiographic response to treatment. One patient, indicated with asterix, withdrew from the study after 8 weeks of treatment to pursue hepatectomy, and one patient, indicated with double asterix, had to stop treatment after 8 weeks for grade 4 hepatotoxicity. (B) Plot showing duration of treatment.

Figure 4 – Kaplan-Meier curves showing (A) progression-free survival and (B) overall survival with panitumumab and vemurafenib combination therapy.
Figure 2.

A

Panitumumab alone
(day 7 biopsy)

Panitumumab +
Vemurafenib
(day 14 on-treatment biopsy)

B

Panitumumab alone
(day 7 biopsy)

Panitumumab +
Vemurafenib
(day 14 on-treatment biopsy)
Figure 4.

A. N=15 (13 Death/progression)
Median PFS: 3.19 months, 99% CI: (1.55-5.29)

B. N=15 (10 Deaths)
Median Survival: 7.6 months, 95% CI: (2.1-not achieved)
Median follow-up for survivors: 10.6 months
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF Mutant Metastatic Colorectal Cancer Patients

Rona Yaeger, Andrea Cercek, Eileen M O'Reilly, et al.

*Clin Cancer Res* Published OnlineFirst January 14, 2015.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-14-2779</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2015/01/15/1078-0432.CCR-14-2779.DC1">http://clincancerres.aacrjournals.org/content/suppl/2015/01/15/1078-0432.CCR-14-2779.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.